Agile Therapeutics Inc.

1.16-0.0500-4.13%Vol 356.29K1Y Perf -54.17%
Jul 23rd, 2021 16:00 DELAYED
BID1.15 ASK1.16
Open1.21 Previous Close1.21
Pre-Market- After-Market1.18
 - -  0.02 1.72%
Target Price
6.25 
Analyst Rating
Strong Buy 1.20
Potential %
438.79 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★+     43.68
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap102.39M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
3.19 
Earnings Date
26th Jul 2021

Today's Price Range

1.151.22

52W Range

1.073.89

5 Year PE Ratio Range

-3.90-4.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.75%
1 Month
-17.14%
3 Months
-36.26%
6 Months
-60.54%
1 Year
-54.17%
3 Years
152.17%
5 Years
-83.09%
10 Years
-

TickerPriceChg.Chg.%
AGRX1.16-0.0500-4.13
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
4.60
5.00
0.35
0.55
-15.80
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
-66.80
-6 643.40
-6 553.40
-
-
RevenueValueIndustryS&P 500US Markets
865.00K
0.01
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.22-0.209.09
Q04 2020-0.23-0.2013.04
Q03 2020-0.18-0.180.00
Q02 2020-0.13-0.127.69
Q01 2020-0.09-0.10-11.11
Q04 2019-0.08-0.10-25.00
Q03 2019-0.08-0.080.00
Q02 2019-0.11-0.0827.27
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.20-17.65Negative
9/2021 QR-0.16-33.33Negative
12/2021 FY-0.68-9.68Negative
12/2022 FY-0.25-127.27Negative
Next Report Date26th Jul 2021
Estimated EPS Next Report-0.21
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume356.29K
Shares Outstanding88.26M
Trades Count1.12K
Dollar Volume3.32M
Avg. Volume1.30M
Avg. Weekly Volume580.52K
Avg. Monthly Volume1.32M
Avg. Quarterly Volume1.05M

Agile Therapeutics Inc. (NASDAQ: AGRX) stock closed at 1.16 per share at the end of the most recent trading day (a -4.13% change compared to the prior day closing price) with a volume of 356.89K shares and market capitalization of 102.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 15 people. Agile Therapeutics Inc. CEO is Alfred Altomari.

The one-year performance of Agile Therapeutics Inc. stock is -54.17%, while year-to-date (YTD) performance is -59.58%. AGRX stock has a five-year performance of -83.09%. Its 52-week range is between 1.07 and 3.89, which gives AGRX stock a 52-week price range ratio of 3.19%

Agile Therapeutics Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 2.87, a price-to-sale (PS) ratio of 119.39, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -69.71%, a ROC of -70.27% and a ROE of -92.97%. The company’s profit margin is -%, its EBITDA margin is -6 553.40%, and its revenue ttm is $865.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Agile Therapeutics Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Agile Therapeutics Inc.’s next earnings report date is 26th Jul 2021.

The consensus rating of Wall Street analysts for Agile Therapeutics Inc. is Strong Buy (1.2), with a target price of $6.25, which is +438.79% compared to the current price. The earnings rating for Agile Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Agile Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Agile Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.65, ATR14 : 0.08, CCI20 : -107.50, Chaikin Money Flow : -0.32, MACD : -0.08, Money Flow Index : 35.87, ROC : -8.66, RSI : 36.28, STOCH (14,3) : 28.13, STOCH RSI : 0.50, UO : 46.19, Williams %R : -71.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Agile Therapeutics Inc. in the last 12-months were: Alfred Altomari (Buy at a value of $57 230), Alfred Altomari (Option Excercise at a value of $166 494), Dennis P. Reilly (Buy at a value of $155 150), Jason Butch (Buy at a value of $20 073), Robert G. Conway (Option Excercise at a value of $14 604)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
5 (83.33 %)
Moderate Buy
1 (20.00 %)
1 (20.00 %)
1 (16.67 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.20
Strong Buy
1.20
Strong Buy
1.17

Agile Therapeutics Inc.

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.

CEO: Alfred Altomari

Telephone: +1 609 683-1880

Address: 101 Poor Farm Road, Princeton 08540, NJ, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

86%14%

Bearish Bullish

52%48%

Bearish Bullish

61%39%

News

Stocktwits